Advertisement
"Kim's appointment as CEO reflects her unique experience and passion tolead all aspects of our business, as I turn my focus to the longer-termstrategy and vision of the organization. This transition marks an importantmilestone for the company, reflecting our leadership and success in deliveringpersonalized medicine to patients," said Randy Scott, chairman of GenomicHealth. "Brad's increasing responsibility as COO recognizes his contributionto the operations of the company and further strengthens our ability todeliver our services to physicians and patients around the world. I lookforward to working with Kim, Brad and our entire management team as wecontinue our efforts to expand worldwide commercialization of the Oncotype DXbreast cancer assay, advance our research and development pipeline, and movethe organization toward profitability."
Advertisement
In addition to Scott, Popovits and Cole, members of the Genomic Healthmanagement team include Steve Shak, chief medical officer; Joffre Baker, chiefscientific officer; David Logan, senior vice president of worldwidecommercialization; Tricia Tomlinson, senior vice president of human resources;and Laura Leber, vice president of corporate communications.
Prior to her appointment as president and CEO, Popovits served aspresident and COO since joining Genomic Health in February 2002, and as adirector since March 2002. Previously, Popovits served in various roles atGenentech, Inc., most recently as senior vice president, marketing and sales.She holds a B.A. in business from Michigan State University.
Cole joined Genomic Health in 2004 as executive vice president and chieffinancial officer and was named executive vice president, operations, andchief financial officer in January 2008. Previously, Cole served in varioussenior management positions at Guidant Corporation and Applied BiosystemsIncorporated. Cole holds a B.S. in business from Biola University and anM.B.A. from San Jose State University.
Genomic Health will present at the 27th Annual JPMorgan HealthcareConference in San Francisco, CA on Wednesday, January 14 at 10:30 a.m. PacificTime. To access the live and subsequently archived webcast of thepresentation, visit the Investor Relations section of Genomic Health's websiteat http://investor.genomichealth.com. Please connect to the website at least15 minutes prior to the beginning of the presentation to allow for anynecessary software downloads. An archived replay will be available for threemonths beginning 24 hours after the live presentation.
About Genomic Health
Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused onthe development and commercialization of genomic-based clinical laboratoryservices for cancer that allow physicians and patients to make individualizedtreatment decisions. In 2004, Genomic Health launched its first test,Oncotype DX(R), which has been shown to predict the likelihood of breastcancer recurrence and the likelihood of chemotherapy benefit in a largeportion of early-stage breast cancer patients. The company was founded in2000 and is located in Redwood City, California. For more information, pleasevisit http://www.genomichealth.com.
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995, including statementsrelating to the ability of the company to continue its efforts to expandworldwide commercialization of the Oncotype DX breast cancer assay, to advanceits research and development pipeline and to move the company towardprofitability, and the company's belief that Mr. Cole's appointment as COOfurther strengthens the company's ability to deliver its services to patientsand physicians around the world. Forward-looking statements are subject torisks and uncertainties that could cause actual results to differ materially.These risks and uncertainties include, but are not limited to: the results ofadditional clinical studies; the applicability of clinical study results toactual outcomes; the risk that we may not obtain or maintain sufficient levelsof reimbursement for our test; the risks and uncertainties associated with theregulation of our tests by FDA; our ability to develop new tests;unanticipated costs or delays in research and development efforts; our abilityto continue to narrow our net loss; our ability to obtain capital when needed;our history of operating losses and the other risks set forth in our filingswith the Securities and Exchange Commission, including the risks set forth inour Quarterly Report on Form 10-Q for the three-month period ended September30, 2008. These forward-looking statements speak only as of the date hereof.Genomic Health disclaims any obligation to update these forward-lookingstatements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Scoreare trademarks or registered trademarks of Genomic Health, Inc. All othertrademarks and service marks are the property of their respective owners.
SOURCE Genomic Health, Inc.
